GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

Overview of attention for article published in Frontiers in oncology, August 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 5 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 7,334 followers.

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins https://t.co/rVgWuNoVsD

12 Nov 2021

Reply Repost Favourite

New research: GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins: We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer… https://t.co/d4

19 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.